Sixteen Thirty Fund

Supports start-ups in the nonprofit advocacy space.

Based in DC

🤖

AI Overview

With $30K in lobbying spend across 6 quarterly filings, Sixteen Thirty Fund is an active lobbying client. Their lobbying covers 3 issue areas. Active from 2021 to 2022.

$30K

Total Spend

Years Active

Firms Hired

Lobbyists Deployed

Issues Lobbied

Spending Trend

View as table

Year	Lobbying Spend
2021	$30K
2022	$0

Issues Lobbied

Health Issues Medicare/Medicaid Pharmacy

Lobbying Firms

Port Side Strategies, LLC

Lobbyists

William Fischer

Government Agencies Targeted

These are the government entities that Sixteen Thirty Fund disclosed contacting in their lobbying filings.

HOUSE OF REPRESENTATIVESOffice of Management & Budget (OMB)SENATEWhite House OfficeU.S. Trade Representative (USTR)

View all agency pressure data →

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Medicare/Medicaid, Pharmacy

Issues related to drug pricing, transparency and accountability.

H.R.597 - Pandemic Treatment Access and Affordability Act of 2021 - in support of bill.

S.833 - Empowering Medicare Seniors to Negotiate Drug Prices Act of 2021 - in support of bill.

Issues raised in

S.833 - Empowering Medicare Seniors to Negotiate Drug Prices Act of 2021 - in support.

S. 415 - Ensuring Innovation Act - in support.

S. 1323. End Price Gouging for Medications Act - in support.

H.R.